Advanced Search

 

Study ID Status Title Patient Level Data
A4010001 Completed A two centre, randomised, partially double-blind, double dummy, placebo-controlled, crossover study to investigate the effects of pre-treatment with a new chemical entity (NCE) and a single inhaled dose of fluticasone propionate (0.5 mg) on the allergen induced late asthmatic response in mild as ...
A4A10003 Completed A randomised, double-blind, placebo-controlled, 3-way cross-over study to investigate the effects of pre-treatment with single inhaled doses of an NCE and fluticasone propionate on the allergen induced late phase asthmatic response in mild asthmatic subjects. Study Listed on ClinicalStudyDataRequest.com
A4A10008 Completed An 8-day, randomised, placebo-controlled, three-way crossover trial of repeat doses of a new chemical entity (NCE), fluticasone propionate and placebo administered intranasally, blinded for fluticasone propionate versus placebo, in an environmental exposition unit, the Vienna Challenge Chamber (VCC) in subjects with seasonal allergic rhinitis (SAR) Study Listed on ClinicalStudyDataRequest.com
A4M105038 Completed Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months Administration of SB-683699 in Subjects with Relapsing-Remitting Multiple Sclerosis
A4M108119 Completed An open-label study of leukocyte counts in the cerebrospinal fluid and blood of subjects with relapsing forms of multiple sclerosis following treatment with firategrast
A4M109079 Completed An open-label, randomised, four period crossover study to investigate the relative pharmacokinetic profiles of tablets from three batches of firategrast with different surface areas and two different tablet formulations containing the same batch of firategrast, given as single 900mg doses to male and female subjects with a diagnosis of Multiple Sclerosis
A6480791 Completed A pharmacokinetic study investigating the rate and extent of absorption of paracetamol and an adjuvant from two different paracetamol formulations.
A6480804 Completed A single dose pharmacoscintigraphic study investigating the differences in gastrointestinal behaviour and paracetamol absorption between two paracetamol formulations
AA210005 Completed A randomised, double-blind, placebo-controlled, cross-over study to investigate the effects of pre-treatment with repeat inhaled doses of a new chemical entity on the allergen-induced late phase asthmatic response in mild asthmatic subjects. Study Listed on ClinicalStudyDataRequest.com
AA210010 Completed A randomised, double-blind, placebo-controlled, rising dose, 6-way crossover study to investigate the effect on heart rate of single doses of GW328267 (25 μg and 50 μg) and escalating cumulative doses of salbutamol (up to 1200 μg) administered alone and in combination to healthy male smokers. Study Listed on ClinicalStudyDataRequest.com
AA210012 Completed A randomised, double-blind, double dummy, placebo-controlled, three-way, balanced incomplete block, crossover study in patients with allergic rhinitis to compare the effect versus placebo of 7 days treatment with a new chemical entity (NCE) and 7 days treatment with intranasal fluticasone propionate 200 μg BID upon nasal clinical response after intranasal allergen challenge. Study Listed on ClinicalStudyDataRequest.com
AA210013 Completed A randomised, double-blind, placebo-controlled, crossover study to investigate the effects of pre-treatment with inhaled repeat doses of a new chemical entity (NCE) on the allergen induced late phase asthmatic response in mild asthmatic subjects. Study Listed on ClinicalStudyDataRequest.com
ABC107442 Completed A retrospective case-control study to estimate the sensitivity and specificity of a pharmacogenetic marker (HLA-B*5701) in subjects with and without hypersensitivity to abacavir.
AC2103473 Completed A randomised, double blind, placebo-controlled, double dummy, 4-way cross-over, dose ascending study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single inhaled doses of GSK233705 and tiotropium bromide (18µg) via DPI in COPD patients Study Listed on ClinicalStudyDataRequest.com
AC2105333 Completed A Randomised, Double-Blind, Placebo-Controlled, Dose Ascending, 3 Period Crossover Study To Examine The Safety, Tolerability, Pharmacodynamics And Pharmacokinetics Of Repeat Inhaled Doses Of GSK233705B In COPD Subjects. Study Listed on ClinicalStudyDataRequest.com
AC2106213 Completed A single-centre, open-label, sequential ascending cross over study to examine safety, tolerability, pharmacodynamics and pharmacokinetics of ascending single doses, nominally 10, 30, 70 and 110µg intravenous doses and a single 250µg oral dose of GSK233705 in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
AC2106956 Completed A multicentre, randomised, partially blinded, placebo-controlled, three-way crossover, incomplete block design study to investigate the safety, tolerability, pharmacodynamics/ efficacy and pharmacokinetics of dual bronchodilator therapy with salmeterol 50µg twice-daily plus two different doses of GSK233705B (20 and 50µg twice-daily), compared with placebo, salmeterol 50µg twice-daily alone, and Tiotropium 18µg once-daily alone, in subjects with chronic obstructive pulmonary disease Study Listed on ClinicalStudyDataRequest.com
AC2108378 Completed A randomised, double-blind, placebo-controlled, dose ascending, 2-cohort, parallel group study to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of twice-daily inhaled doses of GSK233705B formulated with the excipient Magnesium Stearate in COPD subjects for 7-days. Study Listed on ClinicalStudyDataRequest.com
AC2108380 Completed A single-centre, randomized, double-blind placebo-controlled, dose-ascending, cross-over study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705, formulated with the excipient magnesium stearate, in healthy volunteers Study Listed on ClinicalStudyDataRequest.com
AC2110664 Completed Multicentre dose ranging study for once daily GSK233705 in COPD Study Listed on ClinicalStudyDataRequest.com
AC4106889 Completed A single-centre, randomised, double-blind, placebo-controlled, dose-ascending, 3-cohort parallel-group study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of GSK573719 administered as singledoses (750 μg and 1000 μg) and repeat doses over 14 days (250 μg–1000 μg once-daily) of GSK573719 in healthy male and female subjects. Study Listed on ClinicalStudyDataRequest.com
AC4108123 Completed A randomised, double blind, placebo-controlled, double dummy, 4-way cross-over, dose ascending study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK573719 (250, 500 and 1000 μg) and tiotropium bromide (18 μg) via DPI in COPD patients. Study Listed on ClinicalStudyDataRequest.com
AC5108696 Completed A randomized double-blind, placebo-controlled, crossover, dose escalation study to examine the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK1160724 and tiotropium bromide
ACE104325 Completed A randomized, open label comparative study to determine the proportion of asthma patients on SERETIDE Diskus 50/250 mcg b.i.d. achieving Total Control when given medication and compliance enhancement training compared to those receiving medication only
ACT1840 Completed A multicentre pilot study of natural pentasaccharide (SR90107A /Org31540) for the prevention of deep venous thrombosis after total hip replacement.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.